Articles

Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.

A new formulation of Insulin Aspart can offer better glycemic control and may also be given after meals.

New study finds incidence of thyroid disorders in people with diabetes no higher than than those without.

Canagliflozin may reduce the risk of major cardiovascular complication, but amputation risk is increased.

Among long-term users, discontinuation of low-dose aspirin in absence of surgery or bleeding had a greater than 30% increased risk of cardiovascular events.

Second-line treatment is often initiated without evidence of recommended use of first-line treatment.

Recent meta-analysis conducted to address ideal amount of dietary carbohydrates in the management of T2DM.

Trial shows HbA1c reduced, hypoglycemia and DKA similar across study participants.

Increased risk for cardiac events, hospitalization clear predictors of death.

By Guest Writer David Kliff, Diabetic Investor: As we were getting ready to disembark the plane when it arrived in Lisbon I asked a long-term consultant to the diabetes industry why he comes to EASD. “I like to come here because what they have here will show up in our country in two years” was his response. Given what we witnessed at EASD there isn’t much to look forward to in 2019.